rivastigmine has been researched along with Amnesia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Connors, SL; Du, S; Ferreira, JP; Kochendörfer, U; Martin, AN; Slepnev, VI; Verheijen, JC; Wiig, KA | 1 |
| Choubey, PK; Sharma, P; Shrivastava, SK; Tripathi, A | 1 |
| Mishra, DN; Nagpal, K; Singh, SK | 1 |
| Bokde, AL; Born, C; Cavedo, E; Dubois, B; Faltraco, F; Galluzzi, S; Hampel, H; Lista, S; Lopez-Bayo, P; Meindl, T; Möller, HJ; Reiser, M; Teipel, SJ | 1 |
| Chavhan, SS; Joshi, SA; Sawant, KK | 1 |
| Ieni, J; Maurice, T; Meunier, J | 1 |
1 trial(s) available for rivastigmine and Amnesia
| Article | Year |
|---|---|
Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.
Topics: Aged; Aged, 80 and over; Amnesia; Attention; Brain; Brain Mapping; Cognitive Dysfunction; Double-Blind Method; Facial Recognition; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Rivastigmine; Visual Pathways | 2016 |
5 other study(ies) available for rivastigmine and Amnesia
| Article | Year |
|---|---|
Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition.
Topics: Administration, Oral; Amnesia; Amphetamines; Animals; Biogenic Amines; Carbamates; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Phenylcarbamates; Rats; Rivastigmine | 2009 |
Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Male; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pyrrolidines; Rats; Rats, Wistar; Scopolamine; Structure-Activity Relationship | 2020 |
Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety.
Topics: Amnesia; Animals; Behavior, Animal; Body Weight; Brain; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Evaluation, Preclinical; Factor Analysis, Statistical; Male; Maze Learning; Memory; Mice; Nanoparticles; Neuroprotective Agents; Phenylcarbamates; Polysorbates; Rats; Rivastigmine; Scopolamine; Treatment Outcome | 2013 |
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Topics: Amnesia; Animals; Biological Transport; Brain; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Enbucrilate; Lactic Acid; Maze Learning; Mice; Nanoparticles; Neuroprotective Agents; Particle Size; Phenylcarbamates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rivastigmine; Scopolamine | 2010 |
The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.
Topics: Amnesia; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Donepezil; Dose-Response Relationship, Drug; Ethylenediamines; Fluorescent Dyes; Galantamine; Indans; Injections, Intraventricular; Lipid Peroxidation; Male; Maze Learning; Mice; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Phenols; Phenylcarbamates; Piperidines; Receptors, sigma; Rivastigmine; Sulfoxides; Xylenes | 2006 |